Comparison of adverse-event profiles of intravenous low-molecular-weight iron dextran and iron sucrose in peritoneal dialysis patients

Renal Failure

Volumn 33, Issue 3, 2011, Pages 307-311

  Solak, Yalcin ^a   Atalay, Huseyin ^a   Guney, Ibrahim ^b   Turkmen, Kultigin ^a   Kaya, Emine ^a   Turk, Suleyman ^a  

^a SELCUK UNIVERSITY   (Turkey)

^b Meram Research and Training Hospital ^*  (Turkey)

Author keywords

Adverse event; iron sucrose; low molecular weight iron dextran; peritoneal dialysis; safety

Indexed keywords

FERRIC HYDROXIDE SUCROSE; IRON DEXTRAN;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG INFUSION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PRURITUS; RETROSPECTIVE STUDY;

ADULT; AGED; ANEMIA; DEXTRANS; FEMALE; FERRIC COMPOUNDS; HEMATINICS; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERITONEAL DIALYSIS;

EID: 79952681071     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2011.560404     Document Type: Article

References (23)

1. Locatelli F, Del Vecchio L, Pozzoni P. Treating anemia at dif-ferent stages of renal disease. J Nephrol. 2007;20(Suppl. 12): S33-S38. (Pubitemid 351266135)
2. Durand PY. Iron therapy: Is it different with peritoneal dialy-sis compared to hemodialysis? Nephrol Ther. 2006;2(Suppl. 5): S341-S346
3. U.S. Renal Data System (USRDS). 2006 annual data report: Atlas of end-stage renal disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA; 2006.
4. Ahsan N. Infusion of total dose iron versus oral iron supple-mentation in ambulatory peritoneal dialysis patients: A pro-spective, cross-over trial. Adv Perit Dial. 2000;16:80-84.
5. Macdougall IC. How to optimise anaemia therapy in perito-neal dialysis patients. Contrib Nephrol. 2006;150:202-213.
6. Kapoian T, O'Mara NB, Singh AK, et al. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol. 2008;19(2):372-379. (Pubitemid 351240658)
7. St. Peter WL, Obrador GT, Roberts TL, Collins AJ. Trends in intravenous iron use among dialysis patients in the United States (1994-2002). Am J Kidney Dis. 2005;46(4):650-660. (Pubitemid 41383943)
8. Allen JR, Troidle LK, Juergensen PH, Kliger AS, Finkelstein FO. Incidence of peritonitis in chronic peritoneal dialysis patients infused with intravenous iron dextran. Perit Dial Int. 2000;20(6):674-678.
9. Wingard RL, Parker RA, Ismail N, Hakim RM. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis. 1995;25(3):433-439.
10. Bastani B, Galley S. Intraperitoneal iron-dextran as a potential route of iron therapy in CAPD patients. Perit Dial Int. 1996;16(6):646-648.
11. Pecoits-Filho RF, Twardowski ZJ, Kim YL, Khanna R, Morre H, Nolph KD. The absence of toxicity in intraperitoneal iron dextran administration: A functional and histological analysis. Perit Dial Int. 1998;18(1):64-70. (Pubitemid 28184890)
12. Reddy DK, Moore HL, Lee JH, et al. Chronic peritoneal dialysis in iron-deficient rats with solutions containing iron dextran. Kidney Int. 2001;59(2):764-773. (Pubitemid 32157943)
13. Mars RL, Moles K, Pope K, Hargrove P. Use of bolus intrap-eritoneal iron dextran in continuous ambulatory peritoneal dialysis or continuous cyclic peritoneal dialysis patients receiving recombinant human erythropoietin. Adv Perit Dial. 1999; 15:60-64.
14. Prakash S, Walele A, Dimkovic N, Bargman J, Vas S, Ore-opoulos D. Experience with a large dose (500 mg) of intrave-nous iron dextran and iron saccharate in peritoneal dialysis patients. Perit Dial Int. 2001;21(3):290-295. (Pubitemid 32734437)
15. Vychytil A, Haag-Weber M. Iron status and iron supplementa-tion in peritoneal dialysis patients. Kidney Int Suppl. 1999; 69:S71-S78. (Pubitemid 29113587)
16. Li H, Wang SX. Intravenous iron sucrose in peritoneal dialysis patients with renal anemia. Perit Dial Int. 2008;28(2):149-154. (Pubitemid 351552398)
17. Singh H, Reed J, Noble S, Cangiano JL, Van Wyck DB. Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis- stimulating agents for anemia: A ran-domized, controlled trial. Clin J Am Soc Nephrol. 2006; 1(3):475-482.
18. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant. 2006;21(2):378-382. (Pubitemid 43159991)
19. Macdougall IC. Evolution of iv iron compounds over the last century. J Ren Care. 2009;35(Suppl. 2):8-13.
20. Sav T, Tokgoz B, Sipahioglu MH, et al. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran? Ren Fail. 2007;29(4):423-426. (Pubitemid 46752324)
21. Sinha S, Chiu DY, Peebles G, et al. Comparison of intrave-nous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease. J Ren Care. 2009;35(2):67-73.
22. Auerbach M, Al Talib K. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease. Kidney Int. 2008; 73(5):528-530. (Pubitemid 351264124)
23. Auerbach M, Rodgers GM. Intravenous iron. N Engl J Med. 20075;357(1):93-94.